Evaluation immunitically of interleukin-6 level in vaccinated and unvaccinated individuals previously infected with Covid-19 and its effect on P53 protein

Coronavirus 2019 (COVID-19) is a disease epidemic that appeared at the end of 2019, infecting humans and causing many deaths, in addition to its effects on the global economy. The side effects of COVID-19 persist even after recovery and it is called a Post-COVID-19 or long-COVID-19 syndrome. The companies stroke in to produce a vaccine that led to the emergence of the mRNA vaccine which was tested for the first time on humans. The effects of the virus and the vaccine in the medium term after exposure became necessary to study. In this study, interleukin-6 (IL-6) as the most common inflammatory parameter, and protein-53 (P53) associated with cancer in humans, in addition to some biochemical tests were selected. 50 individuals were recruited who infected 3 to 6 months ago as group 1 (G1), and their injury didn't require to use of respiration devices, their ages 25 and 65 years, and 50 individuals were selected who had received the second dose of mRNA vaccine, before 3-6 months ago as group 2 (G2), their ages 25 and 65 years, with 25 healthy people who had not previously shown any symptoms of COVID-19 infection as a control group. While the results of G1 when compared with the control group recorded an important increase for P53 (3960.61±845.00), IgG (26.91±8.28), creatinine (0.75±0.1), TC (200.90±82.14), TG (157.26±61.86), and AST (28.92±8.80), the results were showed a significant decrease for urea (20.6±5.6), UA (4.56±1.1) and ALKP (93.38±30.55). Further, the outcome of this study observed there is no difference between G1 and the control group in terms of IL6 (2.57±1.4), IgM (0.48±0.34), glucose (96.22±12.9), HDL (47.20±11.54), BiliT (0.80±0.47), ALT (29.10±14.92), Ca (9.00±0.38), Na (139.74±6.01), K (4.30±0.48), LDH (192.68±35.20) and CK (122.48±75.36). While the results of the second group compared with the control group showed an important increase in P53 (3782.25±1104.18), IgG (41.58±59.55), glucose (108.84±46.13), creatinine (0.79±0.2), TC (199.20±57.06) and TG (152.16±81.82), the urea (23.32±7.1), ALKP (61.80±27.21) and Na (138.08±3.25) were showed a significant decrease. Also, there were unimportant differences between G2 and the control group in terms of IL6 (2.61±1.5), IgM (0.48±0.36), UA (4.92±1.6), HDL (45.70±10.70), BiliT (0.59±0.44), ALT (25.18±14.61), AST (23.02±9.12), Ca (8.99±0.44), K (5.56±7.11), LDH (172.16±30.03) and CK (131.12±119.81). While the urea (23.32±7.1), ALKP (61.80±27.21), and Na (138.08±3.25) recorded a significant decrease when compared with the control group. The tests for G1 demonstrated a significant increase for P53, IgG, glucose, TC, TG, ALKP, AST, and Na and a significant decrease for UA and Na when comparing with G2, while no significant difference for IL-6, IgM, HDL, BiliT, ALT, Ca, K, LDH, and CK between G1 and G2.